Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”
Pharmacoepidemiology and Drug Safety · 2026-11 · 35 (11)
DOI: 10.1002/pds.70522 ↗Kurz gefasst
Korrektur in der Zeitschrift Pharmacoepidemiology and Drug Safety, online erschienen am 11.11.2026.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”. Pharmacoepidemiology and Drug Safety, 35(11). https://doi.org/10.1002/pds.70522
Vancouver
Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”. Pharmacoepidemiology and Drug Safety. 2026;35(11). doi:10.1002/pds.70522
BibTeX
@article{euvimed2026,
title = {Correction to “Risk of Heart Failure Hospitalization Associated With Hypoxia‐Inducible Factor Prolyl Hydroxylase Inhibitors Versus Erythropoiesis‐Stimulating Agents: A Nationwide Claims‐Based Cohort Study”},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
volume = {35},
number = {11},
doi = {10.1002/pds.70522}
}
EUVIMED